On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer
Uloženo v:
| Název: | On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer |
|---|---|
| Autoři: | Bruno Valentin Sinn, Katharina Sychra, Michael Untch, Thomas Karn, Marion van Mackelenbergh, Jens Huober, Wolfgang Schmitt, Frederik Marmé, Christian Schem, Christine Solbach, Elmar Stickeler, Hans Tesch, Peter A. Fasching, Andreas Schneeweiss, Volkmar Müller, Johannes Holtschmidt, Valentina Nekljudova, Sibylle Loibl, Carsten Denkert |
| Zdroj: | Breast Cancer Res Breast Cancer Research, Vol 26, Iss 1, Pp 1-11 (2024) |
| Informace o vydavateli: | Springer Science and Business Media LLC, 2024. |
| Rok vydání: | 2024 |
| Témata: | Adult, Neoplasm, Residual, Receptor, ErbB-2, Biopsy, Breast Neoplasms, Disease-Free Survival, Breast cancer, Lymphocytes, Tumor-Infiltrating, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, TILs, RC254-282, Aged, Research, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Serial biopsies, Middle Aged, Prognosis, Neoadjuvant Therapy, Ki-67 Antigen, Treatment Outcome, Receptors, Estrogen, Chemotherapy, Adjuvant, Neoadjuvant therapy, Aged [MeSH], Receptor, ErbB-2/metabolism [MeSH], Neoadjuvant Therapy/methods [MeSH], Ki-67 Antigen/metabolism [MeSH], Chemotherapy, Adjuvant/methods [MeSH], Breast Neoplasms/mortality [MeSH], Breast Neoplasms/pathology [MeSH], Female [MeSH], Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Biopsy [MeSH], Receptors, Progesterone/metabolism [MeSH], Humans [MeSH], Treatment Outcome [MeSH], Breast Neoplasms/drug therapy [MeSH], Breast Neoplasms/metabolism [MeSH], Middle Aged [MeSH], Lymphocytes, Tumor-Infiltrating/metabolism [MeSH], Neoplasm, Residual/pathology [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Lymphocytes, Tumor-Infiltrating/immunology [MeSH], Biomarkers, Tumor/metabolism [MeSH], Disease-Free Survival [MeSH], Prognosis [MeSH], Ki-67, Female, Receptors, Progesterone |
| Popis: | Background Patients with pathologic complete response (pCR) to neoadjuvant chemotherapy for invasive breast cancer (BC) have better outcomes, potentially warranting less extensive surgical and systemic treatments. Early prediction of treatment response could aid in adapting therapies. Methods On-treatment biopsies from 297 patients with invasive BC in three randomized, prospective neoadjuvant trials were assessed. BC quantity, tumor-infiltrating lymphocytes (TILs), and the proliferation marker Ki-67 were compared to pre-treatment samples. The study investigated the correlation between residual cancer, changes in Ki-67 and TILs, and their impact on pathologic complete response (pCR) and disease-free survival (DFS). Results Among the 297 samples, 138 (46%) were hormone receptor-positive (HR+)/human epidermal growth factor 2-negative (HER2-), 87 (29%) were triple-negative (TNBC), and 72 (24%) were HER2+. Invasive tumor cells were found in 70% of on-treatment biopsies, with varying rates across subtypes (HR+/HER2-: 84%, TNBC: 62%, HER2+: 51%; p |
| Druh dokumentu: | Article Other literature type |
| ISSN: | 1465-542X |
| DOI: | 10.21203/rs.3.rs-4483953/v1 |
| DOI: | 10.1186/s13058-024-01883-w |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/39317942 https://doaj.org/article/7254adee1eef456f91cca8c6f84490e2 https://repository.publisso.de/resource/frl:6503837 |
| Rights: | CC BY |
| Přístupové číslo: | edsair.doi.dedup.....30b178ccfdb04855cafe14307f234564 |
| Databáze: | OpenAIRE |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Background Patients with pathologic complete response (pCR) to neoadjuvant chemotherapy for invasive breast cancer (BC) have better outcomes, potentially warranting less extensive surgical and systemic treatments. Early prediction of treatment response could aid in adapting therapies. Methods On-treatment biopsies from 297 patients with invasive BC in three randomized, prospective neoadjuvant trials were assessed. BC quantity, tumor-infiltrating lymphocytes (TILs), and the proliferation marker Ki-67 were compared to pre-treatment samples. The study investigated the correlation between residual cancer, changes in Ki-67 and TILs, and their impact on pathologic complete response (pCR) and disease-free survival (DFS). Results Among the 297 samples, 138 (46%) were hormone receptor-positive (HR+)/human epidermal growth factor 2-negative (HER2-), 87 (29%) were triple-negative (TNBC), and 72 (24%) were HER2+. Invasive tumor cells were found in 70% of on-treatment biopsies, with varying rates across subtypes (HR+/HER2-: 84%, TNBC: 62%, HER2+: 51%; p |
|---|---|
| ISSN: | 1465542X |
| DOI: | 10.21203/rs.3.rs-4483953/v1 |